Non-small cell lung cancer stage IIIA

13 trials 8 recruiting MedDRA PT
13 Registered trials
8 Recruiting
10 Unique sponsors
20 Unique IMPs
9 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
L Oncology (ATC L) 8
Mechanism of action (INN-stem analysis)
Unknown / small molecule 9 substances
Antibody-drug conjugate (ADC) 2 substances
Monoclonal antibody (immune) 2 substances
Checkpoint inhibitor (PD-L1) 1 substance
Monoclonal antibody (chimeric) 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Immunosuppressant 1 substance
Monoclonal antibody 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Phase III: 3 Phase II/III: 1 Phase II: 5 Phase I/II: 2 Phase I (Other): 1 Phase I (First in Human): 1

Filter these 13 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 13 trials

Phase III

3 trials
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB; SACITUZUMAB TIRUMOTECAN
    2023-508012-35-00 13 countries 2024 n=258
    Recruiting
  • ETOP IBCSG Partners Foundation Academic
    DURVALUMAB
    2023-508773-82-00 7 countries 2025 n=335
    Recruiting
  • ETOP IBCSG Partners Foundation Academic
    CEMIPLIMAB
    2024-519901-36-00 7 countries 2025 n=300
    Recruiting

Phase II/III

1 trial
  • BioNTech SE Commercial
    BISPECIFIC ANTIBODY AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR A AND PROGRAMMED DEATH-LIGAND 1; BNT327
    2024-515764-31-00 9 countries 2025 n=726
    Recruiting

Phase II

5 trials
  • AstraZeneca AB Commercial
    DATOPOTAMAB DERUXTECAN; DURVALUMAB; FALBIKITUG; INFLIXIMAB; MONALIZUMAB; MYCOPHENOLATE MOFETIL; OLECLUMAB; RILVEGOSTOMIG; VOLRUSTOMIG
    2023-508852-21-00 7 countries 2022 n=493
    Recruiting
  • Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Commercial
    DURVALUMAB
    2024-513948-28-00 1 country 2020 n=57
    Ended
  • Incyte Corp. Commercial
    INCB099280
    2022-502716-37-00 3 countries 2023 n=70
    Ended
  • AIO-Studien gGmbH Academic
    SACITUZUMAB GOVITECAN; ZIMBERELIMAB
    2024-517561-16-00 1 country n=50
    Pending
  • Universita' Degli Studi Di Torino Academic
    PEMBROLIZUMAB
    2024-514701-57-01 1 country n=126
    Pending

Phase I/II

2 trials
  • BioNTech SE Commercial
    BNT326; BNT327
    2024-519344-32-00 4 countries 2026 n=88
    Recruiting
  • BioNTech SE Commercial
    BNT324; BNT327
    2024-520238-31-01 4 countries 2026 n=112 Orphan
    Recruiting

Phase I (Other)

1 trial
  • Systimmune Inc. Commercial
    IMP not specified
    2023-506539-14-00 3 countries 2025 n=95
    Recruiting

Phase I (First in Human)

1 trial
  • Achilles Therapeutics UK Limited Commercial
    ATL001; PEMBROLIZUMAB
    2024-513060-26-00 3 countries 2021 n=24
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
BioNTech SE Commercial 3 Phase II/III, Phase I/II 3
ETOP IBCSG Partners Foundation Academic 2 Phase III 2
Systimmune Inc. Commercial 1 Phase I (Other) 1
AstraZeneca AB Commercial 1 Phase II 1
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Commercial 1 Phase II 0
Incyte Corp. Commercial 1 Phase II 0
Merck Sharp & Dohme LLC Commercial 1 Phase III 1
Achilles Therapeutics UK Limited Commercial 1 Phase I (First in Human) 0
AIO-Studien gGmbH Academic 1 Phase II 0
Universita' Degli Studi Di Torino Academic 1 Phase II 0
New trials by year
2020
1
2021
1
2022
1
2023
1
2024
1
2025
4
2026
2
← All indication landscapes